ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC lessened its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 28.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 17,228 shares of the specialty pharmaceutical company’s stock after selling 6,925 shares during the quarter. Wedge Capital Management L L P NC’s holdings in ANI Pharmaceuticals were worth $1,578,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 126 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in ANI Pharmaceuticals by 2.6% during the second quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company’s stock valued at $816,000 after purchasing an additional 321 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of ANI Pharmaceuticals by 0.8% during the second quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company’s stock worth $3,048,000 after purchasing an additional 351 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of ANI Pharmaceuticals by 10.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 396 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Patrick D. Walsh sold 8,643 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the transaction, the director directly owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. This trade represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the completion of the sale, the director directly owned 25,157 shares of the company’s stock, valued at $2,041,490.55. The trade was a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 28,001 shares of company stock worth $2,446,934 over the last ninety days. 12.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ANIP has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday. HC Wainwright lifted their target price on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Barclays assumed coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price for the company. Truist Financial increased their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Guggenheim raised their price target on ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $80.73 on Wednesday. The company has a 50-day moving average price of $86.38 and a two-hundred day moving average price of $81.90. ANI Pharmaceuticals, Inc. has a 52 week low of $52.74 and a 52 week high of $99.50. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 49.53 and a beta of 0.48. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.